title: Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review).
abstract: Limb-girdle muscular dystrophies (LGMD) are a heterogeneous group of disorders, which has led to certain investigators disputing its rationality. The mutual feature of LGMD is limb-girdle affection. Magnetic resonance imaging (MRI), perioral skin biopsies, blood-based assays, reverse‑protein arrays, proteomic analyses, gene chips and next generation sequencing are the leading diagnostic techniques for LGMD and gene, cell and pharmaceutical treatments are the mainstay therapies for these genetic disorders. Recently, more highlights have been shed on disease biomarkers to follow up disease progression and to monitor therapeutic responsiveness in future trials. In this study, we review LGMD from a variety of aspects, paying specific attention to newly evolving research, with the purpose of bringing this information into the clinical setting to aid the development of novel therapeutic strategies for this hereditary disease. In conclusion, substantial progress in our ability to diagnose and treat LGMD has been made in recent decades, however enhancing our understanding of the detailed pathophysiology of LGMD may enhance our ability to improve disease outcome in subsequent years.
authors.affiliation: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
authors.forename: Omar A
authors.initials: OA
authors.lastname: Mahmood
authors.affiliation: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
authors.forename: Xin Mei
authors.initials: XM
authors.lastname: Jiang
mesh_terms: D000818:Animals; D015415:Biomarkers; D056726:Genetic Association Studies; D006801:Humans; D049288:Muscular Dystrophies, Limb-Girdle / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D015995:Prevalence
chemical_list: D015415:Biomarkers